(19)
(11) EP 3 752 133 A1

(12)

(43) Date of publication:
23.12.2020 Bulletin 2020/52

(21) Application number: 19709204.2

(22) Date of filing: 15.02.2019
(51) International Patent Classification (IPC): 
A61K 9/20(2006.01)
A61K 31/20(2006.01)
A61K 9/16(2006.01)
(86) International application number:
PCT/US2019/018356
(87) International publication number:
WO 2019/161307 (22.08.2019 Gazette 2019/34)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 16.02.2018 US 201862710417 P
30.11.2018 US 201862774083 P

(71) Applicant: Esperion Therapeutics, Inc.
Ann Arbor, MI 48108 (US)

(72) Inventors:
  • LALWANI, Narendra, Dhanraj
    South Lyon, MI 48178 (US)
  • ABDELNASSER, Mohamed
    New York, NY 10956 (US)
  • PINKOSKY, Stephen, Lawrence
    Plymouth, MI 48170 (US)
  • CRAMER, Clay, Thomas
    Dexter, MI 48130 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)

   


(54) SUSTAINED RELEASE FORMULATIONS OF BEMPEDOIC ACID